Company profile
Stemline Therapeutics, Inc.
Privately held: no public share price (Was Nasdaq-listed (STML) but fully acquired by the privately-held Italian Menarini Group in a deal completed 2020-06-10 (~$677M); now operates as a wholly-owned subsidiary of Menarini and is not separately traded. Source: https://www.menarini.com/en-us/news/news-detail/menarini-group-completes-acquisition-of-stemline-therapeutics.html Sources: https://clinicaltrials.gov/study/NCT02661022 Entity resolved by asset-pipeline-v2.)
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Estrogen receptorSmall molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | CD123 | Acute Myeloid Leukemia |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.